Sigilon Therapeutics, Inc.
SGTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $147,446 | $87,934 | $1,511,263 | $731,875 |
| - Cash | $42,066 | $107,143 | $202,229 | $76,069 |
| + Debt | $28,061 | $33,500 | $37,061 | $25,054 |
| Enterprise Value | $133,441 | $14,291 | $1,346,095 | $680,860 |
| Revenue | $12,944 | $9,599 | $13,374 | $14,155 |
| % Growth | 34.8% | -28.2% | -5.5% | – |
| Gross Profit | $12,944 | $9,599 | $13,374 | $14,155 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$38,876 | -$75,010 | -$53,183 | -$42,396 |
| % Margin | -300.3% | -781.4% | -397.7% | -299.5% |
| Net Income | -$43,456 | -$78,236 | -$54,867 | -$44,569 |
| % Margin | -335.7% | -815% | -410.3% | -314.9% |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 |
| % Growth | 95.8% | -40.8% | 17.7% | – |
| Operating Cash Flow | -$51,474 | -$78,405 | -$61,648 | -$50,074 |
| Capital Expenditures | -$537 | -$1,834 | -$972 | -$1,209 |
| Free Cash Flow | -$52,011 | -$80,239 | -$62,620 | -$51,283 |